Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5375628 | 1.00 | CHRNB2 (0.54) | CHRNB2CHRNA4 | |
| SCHEMBL5371277 | 0.91 | CHRNB2 (0.54) | CHRNB2CHRNA4 | |
| SCHEMBL5379713 | 0.91 | CHRNB2 (0.54) | CHRNB2CHRNA4 | |
| SCHEMBL5034072 | 0.88 | CHRNB2 (0.57) | CHRNB2CHRNA4 | |
| SCHEMBL5372510 | 0.88 | CHRNB2 (0.57) | CHRNB2CHRNA4 | |
| SCHEMBL5377564 | 0.86 | CHRNB2 (0.60) | CHRNB2CHRNA4 | |
| SCHEMBL5375888 | 0.86 | CHRNB2 (0.60) | CHRNB2CHRNA4 | |
| SCHEMBL5376135 | 0.83 | CHRNB2 (0.59) | CHRNB2CHRNA4 | |
| SCHEMBL5367480 | 0.83 | CHRNB2 (0.59) | CHRNB2CHRNA4 | |
| SCHEMBL5384744 | 0.82 | CHRNB2 (0.48) | CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030225268-A1 | Diazabicyclic CNS active agents | ABBVIE INC. | 2003-12-04 | — | — | US | claimed |
| EP-1359152-A2 | Diazabicyclic derivatives as nicotinic acetylcholine receptor ligands | ABBOTT LABORATORIES (US) | 2003-11-05 | — | — | EP | claimed |
| US-7265115-B2 | Diazabicyclic CNS active agents | ABBOTT LABORATORIES (US) | 2007-09-04 | — | — | US | disclosed |
| US-20030225268-A1 | Diazabicyclic CNS active agents | ABBVIE INC. | 2003-12-04 | — | — | US | disclosed |
| EP-1359152-A2 | Diazabicyclic derivatives as nicotinic acetylcholine receptor ligands | ABBOTT LABORATORIES (US) | 2003-11-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225268-A1 | Diazabicyclic CNS active agents | GABRE, GRIN1, CNTN1 | CHRNB2 29/4885CHRNA4 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.